BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 11269736)

  • 1. Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumours.
    Caponigro F; Avallone A; Rivellini F; Comella P; Ionna F; De Rosa V; Comella G
    Cancer Chemother Pharmacol; 2001; 47(2):113-6. PubMed ID: 11269736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase I-II trial of the Southern Italy Cooperative Oncology Group (SICOG).
    Caponigro F; Comella P; Rivellini F; Avallone A; Budillon A; Di Gennaro E; Mozzillo N; Ionna F; De Rosa V; Manzione L; Comella G
    Ann Oncol; 2000 May; 11(5):575-80. PubMed ID: 10907951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
    Caponigro F; Avallone A; McLeod H; Cartenì G; De Vita F; Casaretti R; Morsman J; Blackie R; Budillon A; De Lucia L; Gravina A; Catalano G; Comella P; Comella G
    Clin Cancer Res; 1999 Dec; 5(12):3948-55. PubMed ID: 10632324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study.
    Caponigro F; Rosati G; De Rosa P; Avallone A; De Rosa V; De Lucia L; Comella P; Comella G
    Oncology; 2002; 63(3):232-8. PubMed ID: 12381902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy.
    Caponigro F; Avallone A; Budillon A; Comella P; Comella G
    Anticancer Drugs; 2001 Jul; 12(6):489-97. PubMed ID: 11459994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial.
    Comella P; De Vita F; Mancarella S; De Lucia L; Biglietto M; Casaretti R; Farris A; Ianniello GP; Lorusso V; Avallone A; Cartenì G; Leo SS; Catalano G; De Lena M; Comella G
    Ann Oncol; 2000 Oct; 11(10):1323-33. PubMed ID: 11106123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin and raltitrexed combined with leucovorin-modulated 5-fluorouracil i.v. bolus every two weeks: a dose finding study in advanced previously treated colorectal carcinoma. Southern Italy Cooperative Oncology Group.
    Comella P; De Vita F; De Lucia L; Casaretti R; Avallone A; Orditura M; Rivellini F; Palmeri S; Catalano G; Comella G
    Ann Oncol; 2000 Apr; 11(4):461-8. PubMed ID: 10847467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raltitrexed (Tomudex) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: preliminary results from phase I clinical trials.
    Schwartz GK; Harstrick A; González Barón M
    Eur J Cancer; 1999 Mar; 35 Suppl 1():S9-13. PubMed ID: 10645208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of a fixed dose of cisplatin with increasing doses of raltitrexed (Tomudex) in the treatment of patients with locally advanced or metastatic squamous cell carcinoma of the head and neck.
    ten Bokkel Huinink D; Tesselaar ME; Baatenburg de Jong RJ; Verschuur HP; Keizer HJ
    Ann Oncol; 2001 Mar; 12(3):357-63. PubMed ID: 11332149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancer.
    Schwartz GK; Bertino J; Kemeny N; Saltz L; Kelsen DK; Tong W; Welch M; Endres S; Dimery I
    Anticancer Drugs; 2004 Mar; 15(3):219-27. PubMed ID: 15014354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
    Cocconi G; Cunningham D; Van Cutsem E; Francois E; Gustavsson B; van Hazel G; Kerr D; Possinger K; Hietschold SM
    J Clin Oncol; 1998 Sep; 16(9):2943-52. PubMed ID: 9738562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer.
    Vokes EE; Schilsky RL; Weichselbaum RR; Guaspari A; Guarnieri CM; Whaling SM; Panje WR
    Cancer; 1989 Mar; 63(6 Suppl):1048-53. PubMed ID: 2783881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors.
    Vokes EE; Goh BC; Bertucci D; Vogelzang NJ; Mani S; Ratain MJ
    Cancer; 1999 Aug; 86(3):528-32. PubMed ID: 10430263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose intensification of mitoxantrone in combination with levofolinic acid, fluorouracil, cyclophosphamide and granulocyte colony stimulating factor support in advanced untreated breast cancer patients. A multicentric phase II study of the Southern Italy Oncology Group.
    Colucci G; Giotta F; Gebbia V; Riccardi F; Pezzella G; Durini E; Caruso M; Romito S; Gebbia N
    Anticancer Drugs; 1997 Mar; 8(3):257-64. PubMed ID: 9095330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas.
    Gebbia V; Verderame F; Ferraù F; Bordonaro R; Callari A; Caruso M; Tirrito ML; Valenza R; Cicero G; Borsellino N; Tralongo P
    Ann Oncol; 2006 Jun; 17 Suppl 7():vii60-5. PubMed ID: 16760296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed.
    Lewis NL; Scher R; Gallo JM; Engstrom PF; Szarka CE; Litwin S; Adams AL; Kilpatrick D; Brady D; Weiner LM; Meropol NJ
    Cancer Chemother Pharmacol; 2002 Oct; 50(4):257-65. PubMed ID: 12357298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer.
    Vokes EE; Choi KE; Schilsky RL; Moran WJ; Guarnieri CM; Weichselbaum RR; Panje WR
    J Clin Oncol; 1988 Apr; 6(4):618-26. PubMed ID: 3258629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
    Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
    Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells.
    Avallone A; Di Gennaro E; Bruzzese F; Laus G; Delrio P; Caraglia M; Pepe S; Comella P; Budillon A
    Anticancer Drugs; 2007 Aug; 18(7):781-91. PubMed ID: 17581300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer.
    Goto A; Yamada Y; Hosokawa A; Ura T; Arai T; Hamaguchi T; Muro K; Shimada Y; Shirao K
    Int J Clin Oncol; 2004 Oct; 9(5):364-8. PubMed ID: 15549585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.